Developer docs
API playgroundTry for free, no card

Search company profiles

Talus Bio

Full company profile

uuid00006xz

Namestring
Talus Bio
Legal namestring
Talus Bioscience, Inc.
Websiteurl
talus.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Talus Bio (Talus Bioscience, Inc.) is a Seattle-based, privately-held drug discovery biotechnology company founded in 2020 by Alex Federation, PhD and Lindsay Pino, PhD. The company targets transcription factors, cofactors, and splicing regulators — genome-regulating proteins (the 'regulome') historically considered 'undruggable' because they are confined to the nucleus and resist conventional in vitro modeling. Talus Bio's core technology is the proprietary MARMOT platform, anchored on Native Regulome Profiling: a measurement modality described as the first capable of quantifying the activity of 4,000+ genome-regulating proteins in their natural cellular context and over time. MARMOT layers AI-designed chemical libraries, high-throughput cell-based assays generating tens of millions of compound-target interactions per month, and foundation AI models trained on that functional proteomics data, producing a lab-in-the-loop discovery system for small-molecule modulators of regulome activity.

Talus Bio operates a partnership-driven business model that combines (a) internal pipeline development — four disclosed programs in Library Design stage: TBXT for Chordoma and Lung Cancer; NONO/AR-V7 for Castration-Resistant Prostate Cancer; and two transcription factor programs for Solid Tumor and Autoimmune Disease — with (b) external co-development collaborations structured as cost-share and profit-share on out-licensed and commercialized drug products, exemplified by the December 2025 PRISM BioLab agreement for TF and PPI targets. Long-term revenue mechanics point toward licensing, royalties, and milestone payments on out-licensed drug products, with a free Regulome Early Access Program used to seed academic and industry collaborators (whose resulting datasets are open-sourced) and build a community funnel for future partnership demand. Pricing and contract terms are negotiated individually per partnership and are not publicly disclosed.

The company is funded primarily through venture capital and non-dilutive grants. Its most recent equity raise was an $11.2 million Seed+ round in August 2024 led by Two Bear Capital, with participation from NFX, WRF Capital, 50 Years, Boom Capital, Y Combinator Continuity, BoxOne Ventures, FundersClub, and Rolling Bay Ventures; earlier rounds and NIH/NCATS/NCI/NSF grants contribute additional capital. Talus Bio maintains approximately 20 named team members across leadership, advisors, board, and broader team roles, with operations headquartered at 550 17th Avenue, Suite 550, Seattle, WA. The company was recognized in StartUs Insights' '10 New Drug Discovery Companies' roundup and presents at major industry conferences including AACR 2025 and the 2026 J.P. Morgan Healthcare Conference.

Short descriptiontext

Talus Bio is a Seattle-based, venture-backed biotech founded in 2020 that uses its proprietary MARMOT platform — combining AI, functional proteomics, and synthetic chemistry — to discover small-molecule drugs against transcription factors and other previously undruggable genome-regulating proteins for biopharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcription factor drug discovery, regulome profiling platform, AI-enabled proteomics, undruggable target therapeutics, protein-protein interaction modulators
Industry4 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-enabled drug discovery / regulome profiling for transcription factor therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Co-development collaboration revenue share
TypeLicensing Royalties
Description

Talus Bio enters strategic collaborations with pharma/biotech partners (e.g., PRISM BioLab) under which the companies share costs of discovery research and development and share any profits generated from out-licensing and commercialization of discovered drug products.

talus.bio
2Tech Access / Early Access Program partnerships
TypeProfessional Services
Description

Talus Bio offers free Native Regulome Profiling through the Regulome Early Access Program to a small number of academic and industry research groups; this functions as a partnership-seeding model rather than direct revenue. Underlying long-term monetization expected through follow-on partnerships and pipeline out-licensing.

talus.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Strategic co-development collaboration with negotiated cost-share and profit-share on out-licensed products.
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing/financial terms are negotiated per partnership and not publicly disclosed.

talus.bio
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MARMOT
Description

Proprietary AI-enabled drug discovery and regulome profiling platform that measures and modulates the regulome in its native cellular context, generating functional proteomics data used to train foundation AI models for transcription factor drug discovery.

talus.bio
Core offering1 text field

Talus Bio operates the proprietary MARMOT platform, an AI-enabled Native Regulome Profiling platform that combines next-generation proteomics, AI-designed chemical libraries, high-throughput cell-based assays, and foundation AI models to measure and modulate the activity of over 4,000 genome-regulating proteins in their natural cellular context. The platform is used to discover and optimize small-molecule modulators of transcription factor and protein-protein interaction targets, both for internal pipeline programs and for biopharma partners under negotiated co-development agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Closes the gap between 'what is possible now' in cutting-edge regulome research and 'what might be available later' as actionable treatments for transcriptionally driven diseases.
+2 more records
Product overview1 text field

Talus Bio offers a single unified platform — the MARMOT platform — anchored on its proprietary Native Regulome Profiling technology. Native Regulome Profiling is the measurement core that quantifies the activity of over 4,000 genome-regulating proteins in their natural cellular context, and MARMOT layers AI-designed chemical libraries, high-throughput cell-based assays (tens of millions of compound-target interactions per month), and foundation AI models on top of that core to discover and optimize small molecules modulating regulome activity. The platform supports both internal pipeline programs (TBXT for Chordoma/Lung Cancer; NONO/AR-V7 for Castration-Resistant Prostate Cancer; transcription factor programs for Solid Tumor and Autoimmune Disease; additional targets across oncology, immunology, cardiometabolic, and rare disease) and external collaborations, including the Regulome Early Access Program (Tech Access Program) for academic and industry researchers and the December 2025 PRISM BioLab collaboration for transcription factor and protein-protein interaction targets. Together, Native Regulome Profiling, the MARMOT platform, the Tech Access Program, and the internal pipeline programs constitute Talus Bio's integrated regulome drug discovery offering.

Product and service6 records
1MARMOT Platform
CategoryAI-enabled drug discovery platform
Description

Proprietary AI-enabled regulome profiling platform that combines AI-designed chemical libraries, high-throughput cell-based assays (tens of millions of compound-target interactions per month), functional proteomics across thousands of regulome targets, and foundation AI models to discover and optimize small molecules modulating transcription factor and protein-protein interaction activity in live human cells. Offered to biopharma partners via negotiated co-development collaborations.

2Native Regulome Profiling (NRP)
CategoryFunctional proteomics measurement technology
Description

First technology capable of measuring the activity of the over 4,000 genome-regulating proteins in their natural cellular context and over time. It is the foundational measurement capability of the MARMOT platform and is offered to external collaborators through the Regulome Early Access Program (Tech Access Program).

3Regulome Early Access Program (Tech Access Program)
CategoryCollaboration / access program
Description

Collaboration program offering free Native Regulome Profiling, access to Talus Bio's AI-powered analysis pipeline, and direct 1-on-1 collaboration with the Talus Bio platform team to a small number of academic and industry research groups; resulting datasets are open-sourced to the community.

4TBXT Program
CategoryInternal pipeline program
Description

First-in-class internal pipeline program targeting TBXT for Chordoma and Lung Cancer, currently in Library Design stage. Part of Talus Bio's effort to drug previously undruggable targets implicated in oncology and rare disease.

5NONO/AR-V7 Program
CategoryInternal pipeline program
Description

First-in-class internal pipeline program targeting NONO/AR-V7 for Castration-Resistant Prostate Cancer, currently in Library Design stage. Represents Talus Bio's focus on transcription factor and cofactor targets in oncology.

6Transcription Factor Programs (Solid Tumor and Autoimmune Disease)
CategoryInternal pipeline program
Description

First-in-class internal pipeline programs targeting transcription factors for Solid Tumor and Autoimmune Disease indications, currently in Library Design stage. Additional pipeline targets span oncology, immunology, cardiometabolic, and rare disease.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Strategic collaboration announced December 17, 2025, between Talus Bio (Seattle) and PRISM BioLab (Tokyo) to discover novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets. PRISM's proprietary PepMetics small-molecule libraries will be deployed in Talus Bio's AI-guided regulome profiling screens to identify and optimize first-in-class compounds against high-value TF and PPI targets. The companies will share the costs of discovery research and development and any profits from out-licensing and commercialization of discovered drug products.

Strategic tierMinorTypeOthersAnnounced on2025-09-15
Description

University of Washington hosted the inaugural Regulome Summit on September 15, 2025, organized by Talus Bio; the event convened genome scientists, technologists, AI experts, and patient-advocacy organizations (including the Northwest Sarcoma Foundation) to chart a collaborative path toward drugging challenging regulome targets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Publicly traded AI-native drug discovery company combining high-throughput biology with foundation models; comparable to Talus Bio in applying AI/proteomics at scale to discover novel small molecules, but operates across a broader target universe rather than regulome-specific.

TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with high-throughput biology to generate functional datasets for target discovery; comparable in technology philosophy (data-generation loops feeding AI models) and in pursuing historically hard-to-drug targets, with larger scale.

TypeDirect peer
Description

AI-driven biotech using generative models and automated biology to discover novel small molecules, including in oncology and undruggable targets; comparable business model of AI-native discovery with platform-plus-pipeline approach and co-development partnerships with large pharma.

TypeBroad incumbent
Description

Publicly traded computational chemistry and AI drug discovery company serving pharma clients and running an internal pipeline; directly comparable to Talus Bio in pursuing AI/ML-enabled small molecule discovery, with a much broader software-plus-services business model.

TypeDirect peer
Description

AI small-molecule discovery company using structure-based deep learning to screen ultra-large virtual libraries; comparable to Talus Bio as an AI-native small-molecule platform pursuing difficult targets and pharma co-development partnerships.

TypeDirect peer
Description

AI-enabled generative biology company combining deep learning with high-throughput wet-lab validation to design novel proteins and small molecules; comparable in platform-plus-pipeline model and in pursuing pharma co-development partnerships (Christopher Joyce, Talus Bio's VP of BD, previously held a BD role at Absci).

TypeDirect peer
Description

Computational biology company applying genomics, ML, and synthetic chemistry to discover novel therapeutics against historically undruggable targets including transcription factors; closely comparable niche focus on genome-regulating proteins (and an advisor relationship to Talus Bio).

TypeEmerging player
Description

Generative biology company applying foundation models to programmable biomolecule design; comparable in using AI foundation models on proprietary biological data to expand the druggable target universe, though focused on biologics rather than small molecules.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed AI drug discovery company applying DeepMind-derived foundation models to pharma partnerships; comparable in pairing AI foundation models with proprietary biological data and pursuing undruggable targets through large-pharma co-development deals.

TypeEmerging player
Description

Clinical-stage biotech using computational biology and AI for antibody and small-molecule discovery in oncology; comparable in applying AI to transcription-factor and protein-protein-interaction-adjacent oncology targets, though with a more clinical-stage pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Talus Bio

AI-enabled drug discovery / regulome profiling for transcription factor therapeuticstalus.bio

Talus Bio is a Seattle-based, venture-backed biotech founded in 2020 that uses its proprietary MARMOT platform — combining AI, functional proteomics, and synthetic chemistry — to discover small-molecule drugs against transcription factors and other previously undruggable genome-regulating proteins for biopharma partners.

What Talus Bio does

Talus Bio (Talus Bioscience, Inc.) is a Seattle-based, privately-held drug discovery biotechnology company founded in 2020 by Alex Federation, PhD and Lindsay Pino, PhD. The company targets transcription factors, cofactors, and splicing regulators — genome-regulating proteins (the 'regulome') historically considered 'undruggable' because they are confined to the nucleus and resist conventional in vitro modeling. Talus Bio's core technology is the proprietary MARMOT platform, anchored on Native Regulome Profiling: a measurement modality described as the first capable of quantifying the activity of 4,000+ genome-regulating proteins in their natural cellular context and over time. MARMOT layers AI-designed chemical libraries, high-throughput cell-based assays generating tens of millions of compound-target interactions per month, and foundation AI models trained on that functional proteomics data, producing a lab-in-the-loop discovery system for small-molecule modulators of regulome activity.

Talus Bio operates a partnership-driven business model that combines (a) internal pipeline development — four disclosed programs in Library Design stage: TBXT for Chordoma and Lung Cancer; NONO/AR-V7 for Castration-Resistant Prostate Cancer; and two transcription factor programs for Solid Tumor and Autoimmune Disease — with (b) external co-development collaborations structured as cost-share and profit-share on out-licensed and commercialized drug products, exemplified by the December 2025 PRISM BioLab agreement for TF and PPI targets. Long-term revenue mechanics point toward licensing, royalties, and milestone payments on out-licensed drug products, with a free Regulome Early Access Program used to seed academic and industry collaborators (whose resulting datasets are open-sourced) and build a community funnel for future partnership demand. Pricing and contract terms are negotiated individually per partnership and are not publicly disclosed.

The company is funded primarily through venture capital and non-dilutive grants. Its most recent equity raise was an $11.2 million Seed+ round in August 2024 led by Two Bear Capital, with participation from NFX, WRF Capital, 50 Years, Boom Capital, Y Combinator Continuity, BoxOne Ventures, FundersClub, and Rolling Bay Ventures; earlier rounds and NIH/NCATS/NCI/NSF grants contribute additional capital. Talus Bio maintains approximately 20 named team members across leadership, advisors, board, and broader team roles, with operations headquartered at 550 17th Avenue, Suite 550, Seattle, WA. The company was recognized in StartUs Insights' '10 New Drug Discovery Companies' roundup and presents at major industry conferences including AACR 2025 and the 2026 J.P. Morgan Healthcare Conference.

Talus Bio firmographics

Firmographics
Name
Talus Bio
Legal name
Talus Bioscience, Inc.
Website
https://talus.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Talus Bio is a Seattle-based, venture-backed biotech founded in 2020 that uses its proprietary MARMOT platform — combining AI, functional proteomics, and synthetic chemistry — to discover small-molecule drugs against transcription factors and other previously undruggable genome-regulating proteins for biopharma partners.
Ownership category
akta.pro rank

Talus Bio industry classification

Industry
Product category
AI-enabled drug discovery / regulome profiling for transcription factor therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Transcription factor drug discovery
  • Regulome profiling platform
  • AI-enabled proteomics
  • Undruggable target therapeutics
  • Protein-protein interaction modulators

Where Talus Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Talus Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Co-development collaboration revenue share: Talus Bio enters strategic collaborations with pharma/biotech partners (e.g., PRISM BioLab) under which the companies share costs of discovery research and development and share any profits generated from out-licensing and commercialization of discovered drug products.
  2. Tech Access / Early Access Program partnerships: Talus Bio offers free Native Regulome Profiling through the Regulome Early Access Program to a small number of academic and industry research groups; this functions as a partnership-seeding model rather than direct revenue. Underlying long-term monetization expected through follow-on partnerships and pipeline out-licensing.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractStrategic co-development collaboration with negotiated cost-share and profit-share on out-licensed products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Talus Bio product offering

Product offering

Core offering

Talus Bio operates the proprietary MARMOT platform, an AI-enabled Native Regulome Profiling platform that combines next-generation proteomics, AI-designed chemical libraries, high-throughput cell-based assays, and foundation AI models to measure and modulate the activity of over 4,000 genome-regulating proteins in their natural cellular context. The platform is used to discover and optimize small-molecule modulators of transcription factor and protein-protein interaction targets, both for internal pipeline programs and for biopharma partners under negotiated co-development agreements.

Product overview

Talus Bio offers a single unified platform — the MARMOT platform — anchored on its proprietary Native Regulome Profiling technology. Native Regulome Profiling is the measurement core that quantifies the activity of over 4,000 genome-regulating proteins in their natural cellular context, and MARMOT layers AI-designed chemical libraries, high-throughput cell-based assays (tens of millions of compound-target interactions per month), and foundation AI models on top of that core to discover and optimize small molecules modulating regulome activity. The platform supports both internal pipeline programs (TBXT for Chordoma/Lung Cancer; NONO/AR-V7 for Castration-Resistant Prostate Cancer; transcription factor programs for Solid Tumor and Autoimmune Disease; additional targets across oncology, immunology, cardiometabolic, and rare disease) and external collaborations, including the Regulome Early Access Program (Tech Access Program) for academic and industry researchers and the December 2025 PRISM BioLab collaboration for transcription factor and protein-protein interaction targets. Together, Native Regulome Profiling, the MARMOT platform, the Tech Access Program, and the internal pipeline programs constitute Talus Bio's integrated regulome drug discovery offering.

Differentiator

Problem solved

Functional benefit

Brands

  • MARMOT: Proprietary AI-enabled drug discovery and regulome profiling platform that measures and modulates the regulome in its native cellular context, generating functional proteomics data used to train foundation AI models for transcription factor drug discovery.

Products and services

  • MARMOT Platform Proprietary AI-enabled regulome profiling platform that combines AI-designed chemical libraries, high-throughput cell-based assays (tens of millions of compound-target interactions per month), functional proteomics across thousands of regulome targets, and foundation AI models to discover and optimize small molecules modulating transcription factor and protein-protein interaction activity in live human cells. Offered to biopharma partners via negotiated co-development collaborations.
  • Native Regulome Profiling (NRP) First technology capable of measuring the activity of the over 4,000 genome-regulating proteins in their natural cellular context and over time. It is the foundational measurement capability of the MARMOT platform and is offered to external collaborators through the Regulome Early Access Program (Tech Access Program).
  • Regulome Early Access Program (Tech Access Program) Collaboration program offering free Native Regulome Profiling, access to Talus Bio's AI-powered analysis pipeline, and direct 1-on-1 collaboration with the Talus Bio platform team to a small number of academic and industry research groups; resulting datasets are open-sourced to the community.
  • TBXT Program First-in-class internal pipeline program targeting TBXT for Chordoma and Lung Cancer, currently in Library Design stage. Part of Talus Bio's effort to drug previously undruggable targets implicated in oncology and rare disease.
  • NONO/AR-V7 Program First-in-class internal pipeline program targeting NONO/AR-V7 for Castration-Resistant Prostate Cancer, currently in Library Design stage. Represents Talus Bio's focus on transcription factor and cofactor targets in oncology.
  • Transcription Factor Programs (Solid Tumor and Autoimmune Disease) First-in-class internal pipeline programs targeting transcription factors for Solid Tumor and Autoimmune Disease indications, currently in Library Design stage. Additional pipeline targets span oncology, immunology, cardiometabolic, and rare disease.

Quantifiable outcome

  • Closes the gap between 'what is possible now' in cutting-edge regulome research and 'what might be available later' as actionable treatments for transcriptionally driven diseases.
  • +2 more outcomes

Companies that use Talus Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Talus Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Talus Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship / core and minor.

  • PRISM BioLab Co., Ltd.flagship / coreStrategic or Co-development Partner · 17 December 2025Strategic collaboration announced December 17, 2025, between Talus Bio (Seattle) and PRISM BioLab (Tokyo) to discover novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets. PRISM's proprietary PepMetics small-molecule libraries will be deployed in Talus Bio's AI-guided regulome profiling screens to identify and optimize first-in-class compounds against high-value TF and PPI targets. The companies will share the costs of discovery research and development and any profits from out-licensing and commercialization of discovered drug products.
  • University of Washington (Regulome Summit host venue)minorOthers · 15 September 2025University of Washington hosted the inaugural Regulome Summit on September 15, 2025, organized by Talus Bio; the event convened genome scientists, technologists, AI experts, and patient-advocacy organizations (including the Northwest Sarcoma Foundation) to chart a collaborative path toward drugging challenging regulome targets.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Talus Bio competitors and assessment

Company assessment

Broad incumbents

  • Recursion Pharmaceuticals: Publicly traded AI-native drug discovery company combining high-throughput biology with foundation models; comparable to Talus Bio in applying AI/proteomics at scale to discover novel small molecules, but operates across a broader target universe rather than regulome-specific.
  • Schrödinger: Publicly traded computational chemistry and AI drug discovery company serving pharma clients and running an internal pipeline; directly comparable to Talus Bio in pursuing AI/ML-enabled small molecule discovery, with a much broader software-plus-services business model.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind-derived foundation models to pharma partnerships; comparable in pairing AI foundation models with proprietary biological data and pursuing undruggable targets through large-pharma co-development deals.

Direct peers

  • Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to generate functional datasets for target discovery; comparable in technology philosophy (data-generation loops feeding AI models) and in pursuing historically hard-to-drug targets, with larger scale.
  • Insilico Medicine: AI-driven biotech using generative models and automated biology to discover novel small molecules, including in oncology and undruggable targets; comparable business model of AI-native discovery with platform-plus-pipeline approach and co-development partnerships with large pharma.
  • Atomwise: AI small-molecule discovery company using structure-based deep learning to screen ultra-large virtual libraries; comparable to Talus Bio as an AI-native small-molecule platform pursuing difficult targets and pharma co-development partnerships.
  • Absci: AI-enabled generative biology company combining deep learning with high-throughput wet-lab validation to design novel proteins and small molecules; comparable in platform-plus-pipeline model and in pursuing pharma co-development partnerships (Christopher Joyce, Talus Bio's VP of BD, previously held a BD role at Absci).
  • Hexagon Bio: Computational biology company applying genomics, ML, and synthetic chemistry to discover novel therapeutics against historically undruggable targets including transcription factors; closely comparable niche focus on genome-regulating proteins (and an advisor relationship to Talus Bio).

Emerging players

  • Generate Biomedicines: Generative biology company applying foundation models to programmable biomolecule design; comparable in using AI foundation models on proprietary biological data to expand the druggable target universe, though focused on biologics rather than small molecules.
  • Adagene: Clinical-stage biotech using computational biology and AI for antibody and small-molecule discovery in oncology; comparable in applying AI to transcription-factor and protein-protein-interaction-adjacent oncology targets, though with a more clinical-stage pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Talus Bio social profiles

Digital presence

Talus Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Talus Bio leadership team

Management profile

Number of profiles

Profiles5 records

Talus Bio funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Talus Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Talus Bio

What does Talus Bio do?

Talus Bio operates the proprietary MARMOT platform, an AI-enabled Native Regulome Profiling platform that combines next-generation proteomics, AI-designed chemical libraries, high-throughput cell-based assays, and foundation AI models to measure and modulate the activity of over 4,000 genome-regulating proteins in their natural cellular context. The platform is used to discover and optimize small-molecule modulators of transcription factor and protein-protein interaction targets, both for internal pipeline programs and for biopharma partners under negotiated co-development agreements.

Is Talus Bio a public or private company?

Talus Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Talus Bio founded?

Talus Bio was founded in 2020. It employs 11 to 50 people.

Where is Talus Bio based?

Talus Bio is headquartered in Seattle, United States, in the North America region.

How does Talus Bio make money?

Two revenue lines are on record. Co-development collaboration revenue share is the primary driver. The others are tech Access / Early Access Program partnerships.

Who are Talus Bio's main competitors?

Broad incumbents on record are Recursion Pharmaceuticals, Schrödinger and Isomorphic Labs. Direct peers are Insitro, Insilico Medicine, Atomwise, Absci and Hexagon Bio. Emerging players are Generate Biomedicines and Adagene.

Does Talus Bio have an API?

No public API is recorded for Talus Bio.

What industry is Talus Bio in?

Talus Bio's product category is AI-enabled drug discovery / regulome profiling for transcription factor therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceTalus Bio Launches Ptarmigan-1, the First Structure-Free AI Model for Proteome-Wide Drug DiscoveryTalus Bio released Ptarmigan-1, the first structure-free AI model that predicts small-molecule binding across the human proteome, including disordered proteins. It outperformed structure-based methods on a STAT6 inhibitor series and screens 3.4 billion compounds daily. The model is available via a public portal, with Talus Bio open to collaborations.PR NewswirePRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction TargetsPRISM BioLab and Talus Bioscience announced a collaboration to discover novel inhibitors of transcription factor and protein-protein interaction targets. The partnership combines PRISM's PepMetics® chemistry with Talus Bio's AI-guided regulome profiling screens to identify compounds against challenging therapeutic targets. Both companies will share the costs of discovery research and any profits generated from commercialization.PR Newswire APACPRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction TargetsPRISM BioLab and Talus Bioscience have entered into a collaboration to discover novel inhibitors of transcription factor and protein-protein interaction targets, combining Talus Bio's assay technologies and AI-guided regulome profiling with PRISM's small-molecule libraries. The companies will share research costs and any profits from out-licensing or commercialization of discovered drug products. The collaboration aims to develop first-in-class compounds with direct functional effects on TF and PPI activity in live human cells, targeting historically 'undruggable' proteins.VatorNewsAI drug discovery company Talus Bioscience raises $11.2MTalus Bioscience raised $11.2 million in a seed+ round led by Two Bear Capital. The company's MARMOT platform identifies molecules to block disease-causing transcription factors, and the funds will advance therapeutic programs and expand its AI/ML team.TmcnetTalus Bioscience Announces $11.2M in New Funding Led by Two Bear Capital to Advance AI Platform for Transcription Factor Therapeutic DiscoveryTalus Bioscience announced $11.2M in new venture funding led by Two Bear Capital, with participation from other investors. The Seed+ round will advance its MARMOT AI platform for transcription factor therapeutic discovery, targeting Brachyury-driven cancers and prostate cancer. The company has previously secured $19.7M in venture funding and six non-dilutive grants.Business Wire BlogTalus Bioscience Announces $11.2M in New Funding Led by Two Bear Capital to Advance AI Platform for Transcription Factor Therapeutic DiscoveryTalus Bioscience announced $11.2M in Seed+ funding led by Two Bear Capital to advance its MARMOT AI platform for transcription factor modulators. The company will use the funds to develop programs targeting Brachyury-driven cancers and an undruggable prostate cancer transcription factor. The funding brings total venture capital to $19.7M.YahooTalus Bioscience Announces $11.2M in New Funding Led by Two Bear Capital to Advance AI Platform for Transcription Factor Therapeutic DiscoveryTalus Bioscience announced $11.2M in Seed+ funding led by Two Bear Capital to advance its MARMOT AI platform for transcription factor modulators. The round will support programs targeting Brachyury-driven cancers and an undruggable prostate cancer transcription factor. The company has previously secured $19.7M in venture funding.Business Wire BlogTalus Bioscience Announces $11.2M in New Funding Led by Two Bear Capital to Advance AI Platform for Transcription Factor Therapeutic DiscoveryTalus Bioscience announced $11.2M in new venture funding led by Two Bear Capital, with participation from other investors. The Seed+ round will advance its MARMOT AI platform for discovering transcription factor modulators, targeting previously undruggable targets. The company has previously secured $19.7M in venture funding and six non-dilutive grants.Venture Capital Access OnlineTalus Bioscience Announces $11.2M in New Funding Led by Two Bear Capital to Advance AI Platform for Transcription Factor Therapeutic DiscoveryTalus Bioscience has raised $11.2 million in a Seed+ funding round led by Two Bear Capital to enhance its MARMOT platform, which uses AI for therapeutic discovery against difficult targets. The funding will help advance therapeutic programs for cancers and other diseases driven by transcription factors, allowing for faster identification of drug candidates from vast compound databases. This investment underscores the potential of Talus Bioscience's innovative approach in transforming treatment strategies for complex diseases.VC News DailyTalus Bioscience Nabs $11.2M Seed+ RoundTalus Bioscience, a Seattle-based drug discovery company, announced $11.2 million in Seed+ venture funding led by Two Bear Capital with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures. Founded in 2020 by Alex Federation and Lindsay Pino, the company develops therapeutics targeting previously undruggable transcription factors using its proprietary MARMOT platform that integrates AI, proteomics, synthetic chemistry, and computational biology. The funding will support the company's growth as it advances its drug discovery pipeline.